Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$2.8MFederal grants as PI3 awards
5Patents grantedLatest Oct 1, 2024
568Papers5,408 citations
Federal awards and patents by year
AwardsPatents
3 awards · $2.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 11, 2020 | NIH | SBIR Phase II Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma | $999K | ONCOCEUTICS, INC. |
| Aug 7, 2019 | NIH | SBIR Phase II Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma | $1000K | ONCOCEUTICS, INC. |
| Aug 6, 2019 | NIH | SBIR Phase II Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer | $777K | ONCOCEUTICS, INC. |
6 patents as inventor
- US 10172862ONCOCEUTICS, INC.Jan 8, 2019
- US 10369154ONCOCEUTICS, INC.Aug 6, 2019
- US 10946022ONCOCEUTICS, INC.Mar 16, 2021
- US 11116771ONCOCEUTICS, INC.Sep 14, 2021
- US 12102639ONCOCEUTICS, INC.Oct 1, 2024
- US ONCOCEUTICS, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#686
Awards as PI#822
Patents#25
Companies
- ONCOCEUTICS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.